Lemborexant: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
Expand Lemborexant with Stahl-sourced detail (with skepticism) |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| Line 14: | Line 14: | ||
| pregnancy = Limited data; avoid | | pregnancy = Limited data; avoid | ||
| legal = Rx, Schedule IV (US) | | legal = Rx, Schedule IV (US) | ||
| intro = '''Lemborexant''' (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) FDA-approved in December 2019 for insomnia in adults. Among DORAs, lemborexant has faster receptor association/dissociation kinetics than suvorexant | | intro = '''Lemborexant''' (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) FDA-approved in December 2019 for insomnia in adults. Among DORAs, lemborexant has faster receptor association/dissociation kinetics than suvorexant, which is hypothesized to facilitate sleep onset while still maintaining adequate duration of antagonism for sleep maintenance. The 17-19 hour half-life can produce some next-day residual sedation in sensitive individuals. | ||
DORAs broadly produce sleep that more closely resembles physiologic sleep architecture than GABAergic hypnotics, with reduced REM suppression. Side effect profile favorable compared to benzodiazepines, but sleep paralysis, sleep-related hallucinations, and complex sleep behaviors have been reported. | DORAs broadly produce sleep that more closely resembles physiologic sleep architecture than GABAergic hypnotics, with reduced REM suppression. Side effect profile favorable compared to benzodiazepines, but sleep paralysis, sleep-related hallucinations, and complex sleep behaviors have been reported. | ||